AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

R represents:

(i) ~~hydrogen, halogen, cyano or C_1-C_2 haloalkyl, or~~

(ii) ~~C_1-C_4alkyl, C_2-C_4alkenyl, C_2-C_4alkynyl, C_1-C_2alkanoyl, C_3-C_7cycloalkyl, C_3-C_7cycloalkenyl or heterocycloalkyl, each of which is optionally substituted;~~

R_1 represents:

(i) hydrogen, hydroxy, halogen, amino, cyano, nitro, C_1-C_2haloalkyl or C_1-C_2 haloalkoxy;

(ii) C_1-C_4alkyl, C_2-C_4alkenyl, C_1-C_4alkoxy, C_3-C_7cycloalkyl, (C_3-C_7cycloalkyl)C_1-C_2alkyl, or mono- or di-C_1-C_6alkylamino, or

(iii) phenylC_0-C_4carbhydryl or (5- or 6-membered heteroaryl)C_0-C_4carbhydryl, each of which is optionally substituted;

R_2 is optionally substituted C_1-C_7 alkyl or optionally substituted C_2-C_7 alkenyl;

R_3 is hydrogen or C_1-C_6alkyl;

R_4 represents:

~~(i) C_1-C_6alkyl, C_2-C_6alkenyl or C_2-C_6alkynyl, each of which is optionally substituted;~~

(ii)(i) optionally substituted arylC_0-C_2alkyl having 1 ring or 2 fused rings; or

(iii)(ii) optionally substituted arylC_1-C_2alkyl, wherein the aryl portion is fused to a 5- to 7-membered saturated or partially unsaturated ring having 0, 1 or 2 ring atoms independently chosen from N, O and S, with remaining ring atoms being carbon; or

(iv) ~~optionally substituted (4-to-12-membered heterocycle)C_0-C_4alkyl;~~

R_5 and R_6 are independently chosen from hydrogen and C_1-C_6alkyl; and

Ar represents:

(i) optionally substituted aryl having 1 ring or 2 fused or pendant rings; or

(ii) optionally substituted phenyl fused to a 5- to 7-membered saturated or partially unsaturated ring having 0, 1 or 2 ring atoms independently chosen from N, O and S, with remaining ring atoms being carbon; or

(iii) optionally ~~substituted heteroaryl having 1 ring or 2 fused or pendant rings, from 5 to 7 members in each ring, and in at least one ring from 1 to 3 heteroatoms independently selected from N, O and S~~.

2. (Currently Amended) A compound or pharmaceutically acceptable form thereof according to claim 1, wherein:

R represents:

(i) ~~hydrogen,~~ halogen, ~~cyano or C_1-C_2haloalkyl;~~ or

(ii) ~~C_1-C_4alkyl, C_2-C_4alkenyl, C_2-C_4alkynyl, C_1-C_2alkanoyl, C_3-C_7cycloalkyl, C_3-C_7 cycloalkenyl or~~ 5- to 7-membered heterocycloalkyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, oxo, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_2alkoxycarbonyl;

R_1 represents:

(i) hydrogen, hydroxy, halogen, amino, cyano, nitro, C_1-C_2haloalkyl or C_1-C_2 haloalkoxy;

(ii) C_1-C_4alkyl, C_2-C_4alkenyl, C_2-C_4alkynyl, C_1-C_4alkoxy, C_3-C_7cycloalkyl, (C_3-C_7cycloalkyl)C_1-C_2alkyl, or mono- or di-C_1-C_4alkylamino, each of which is substituted with from 0 to 3 substituents independently chosen from hydrogen, hydroxy, halogen, amino, cyano, oxo, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_2alkoxycarbonyl; or

(iii) phenylC_0-C_4carbhydryl or (5- or 6-membered heteroaryl)C_0-C_4carbhydryl, wherein each 5- or 6-membered heteroaryl is independently chosen from imidazolyl, pyridyl, thiazolyl, pyrimidinyl and thienyl, and wherein each phenylC_0-C_4carbhydryl or (5- or 6-membered heteroaryl)C_0-C_4carbhydryl is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, nitro, -COOH, -

$CONH_2$, $-SO_2NH_2$, C_1-C_2 haloalkyl, C_1-C_2 haloalkoxy, C_1-C_4 alkyl, C_1-C_4alkoxy, C_2-C_4alkanoyl, C_1-C_2alkylsulfonyl, C_1-C_2alkylsulfinyl and C_1-C_2alkylthio;

R_2 is C_1-C_7alkyl or C_2-C_7alkenyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, oxo, C_1-C_2alkoxy, C_1-C_2 mono-and di-alkylamino, C_3-C_7cycloalkyl and phenyl;

R_3 is hydrogen or C_1-C_6alkyl;

R_1 represents:

~~(i) C_1-C_6alkyl, C_2-C_6 alkenyl or C_2-C_6 alkynyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C_1-C_2alkyl, C_1-C_2alkoxy, or C_1-C_2alkoxycarbonyl;~~

(ii)(i) arylC_0-C_2alkyl having 1 ring or 2 fused rings; or

(iii)(ii) benzyl fused to a 5- to 7-membered saturated or partially unsaturated ring having 0, 1 or 2 ring atoms independently chosen from N, O and S with remaining ring atoms being carbon; or

~~(iv) (4 to 12 membered heterocycle)C_0-C_2alkyl;~~

wherein each of (ii) and (iii) ~~(iv)~~ is substituted with from 0 to 4 substituents independently chosen from hydroxy, halogen, amino, cyano, nitro, -COOH, $-CONH_2$, $-SO_2NH_2$, oxo, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, C_1-C_4alkyl, C_1-C_4alkoxy, mono- and di-(C_1-C_6)alkylamino, C_1-C_4alkanoyl, C_1-C_2sulfonate, C_1-C_2alkylsulfonyl, C_1-C_2alkylsulfinyl, C_1-C_4alkylthio, C_2-C_4alkanone, C_1-C_4alkyl ester; C_1-C_4alkanoyloxy, C_1-C_2alkoxycarbonyl and C_1-C_2alkylcarboxamido; and

Ar represents:

(i) an aryl group having 1 ring or 2 fused or pendant rings; or

(ii) phenyl fused to a 5- to 7-membered saturated or partially unsaturated ring having 0, 1 or 2 ring atoms independently chosen from N, O and S with remaining ring atoms being carbon; or

(iii) a heteroaryl group ~~having 1 ring or 2 fused or pendant rings, from 5 to 7 members in each ring, and in at least one ring from 1 to 3 heteroatoms selected from N, O, and S;~~

each of which is substituted with from 0 to 4 substituents independently chosen from hydroxy, halogen, amino, cyano, nitro, -COOH, $-CONH_2$, $-SO_2NH_2$, oxo, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, C_1-C_4alkyl, C_1-C_4alkoxy, mono- and di-(C_1-C_6)alkylamino, C_1-C_4alkanoyl, C_1-C_2sulfonate, C_1-C_2alkylsulfonyl, C_1-C_2alkylsulfinyl, C_1-C_4alkylthio, C_2-C_4alkanone, C_1-C_4alkyl ester, C_1-C_4alkanoyloxy, C_1-C_2alkoxycarbonyl and C_1-C_2alkylcarboxamido.

3. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein R_5 is hydrogen, and R_6 is hydrogen, methyl or ethyl.

4. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein R_1 is phenyl substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, nitro, -COOH, $-CONH_2$, $-SO_2NH_2$, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, C_1-C_4alkyl, C_1-C_4alkoxy, C_2-C_4alkanoyl, C_1-C_2alkylsulfonyl, C_1-C_2alkylsulfinyl and C_1-C_2alkylthio.

5. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein R_1 is phenyl substituted with 1 or 2 substituents independently chosen from hydroxy, halogen, amino, cyano, nitro, -COOH, $-CONH_2$, $-SO_2NH_2$, C_1-C_2 haloalkyl, C_1-C_2 haloalkoxy, C_1-C_2alkyl and C_1-C_2alkoxy.

6. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2 wherein R_1 is unsubstituted phenyl.

7. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein R_1 is hydrogen, hydroxy, halogen, amino, cyano, trifluoromethyl, pentafluoroethyl, difluoromethyl, trifluoromethoxy or difluoromethoxy.

8. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein R_1 is halogen.

9. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein R_2 is propyl, butyl, pentyl or 3-methylbutyl.

10. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein R_3 is hydrogen.

11. (Cancelled).

12. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein R_4 is benzyl substituted with from 0 to 4 substituents independently chosen from hydroxy, halogen, amino, cyano, nitro, -COOH, $-CONH_2$, $-SO_2NH_2$, oxo, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, C_1-C_4alkyl, C_1-C_4alkoxy, mono- and di-(C_1-C_6)alkylamino, C_1-C_4alkanoyl, C_1-C_2sulfonate, C_1-C_2alkylsulfonyl, C_1-C_2alkylsulfinyl, C_1-C_4alkylthio, C_2-C_4alkanone, C_1-C_4alkyl ester, C_1-C_4alkanoyloxy, C_1-C_2alkoxycarbonyl and C_1-C_2alkylcarboxamido.

13. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein R_4 is benzyl substituted with from 0 to 2 substituents independently chosen from hydroxy, halogen, amino, cyano, -COOH, $-CONH_2$, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, C_1-C_2alkyl, mono- and di-(C_1-C_2)alkylamino, C_1-C_2alkoxy, C_1-C_2alkanoyl and C_1-C_2alkoxycarbonyl.

14. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein R_4 is benzyl fused to a 5- to 7-membered saturated or partially unsaturated ring having 0, 1 or 2 ring atoms chosen from N, O, and S with remaining ring atoms being carbon, wherein the benzyl fused to a 5- to 7-membered ring is substituted with from 0 to 4 substituents independently chosen from hydroxy, halogen, amino, cyano, -COOH, $-CONH_2$, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, C_1-C_2alkyl, mono- and di-(C_1-C_2)alkylamino, C_1-C_2alkoxy, C_1-C_2alkanoyl and C_1-C_2alkoxycarbonyl.

15. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein R_4 is benzo[1,3]dioxol-5-ylmethyl, 2,3-dihydro-1-benzofuran-

6-ylmethyl, 2,3-dihydro-1-benzofuran-5-ylmethyl, chroman-6-ylmethyl, chroman-7-ylmethyl, 1H-indol-5-yl, 1H-indazol-5-yl, 1,2,3,4-tetrahydro-quinolin-6-yl or 2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl, each of which is substituted with from 0 to 2 substituents independently chosen from hydroxy, halogen, C_1-C_2 alkyl and C_1-C_2alkoxy.

16. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein R_4 is benzo[1,3]dioxol-5-ylmethyl or 2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl.

17. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein Ar represents phenyl substituted with from 0 to 4 substituents independently chosen from hydroxy, halogen, amino, cyano, nitro, -COOH, -$CONH_2$, -SO_2NH_2, oxo, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, C_1-C_4alkyl, C_1-C_4alkoxy, mono- and di-(C_1-C_6)alkylamino, C_1-C_4alkanoyl, C_1-C_2sulfonate, C_1-C_2alkylsulfonyl, C_1-C_2alkylsulfinyl, C_1-C_4alkylthio, C_2-C_4alkanone, C_1-C_4alkylester, C_1-C_4alkanoyloxy; C_1-C_2alkoxycarbonyl and C_1-C_2alkylcarboxamido.

18. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein Ar represents phenyl substituted with from 0 to 2 substituents independently chosen from hydroxy, halogen, amino, cyano, -COOH, -$CONH_2$, C_1-C_2 haloalkyl, C_1-C_2haloalkoxy, C_1-C_2alkyl, mono- and di-(C_1-C_2alkyl)amino, C_1-C_2alkoxy, C_1-C_2alkanoyl and C_1-C_2alkoxycarbonyl.

19. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein Ar represents phenyl fused to a 5- to 7-membered saturated or partially unsaturated ring having 0, 1 or 2 ring atoms independently chosen from N, O and S with remaining ring atoms being carbon, and wherein the phenyl fused to a 5- to 7-membered ring is substituted with from 0 to 4 substituents independently chosen from hydroxy, halogen, amino, cyano, -COOH, -$CONH_2$, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, C_1-C_2alkyl, mono- and di-(C_1-C_2)alkylamino, C_1-C_2alkoxy, C_1-C_2alkanoyl and C_1-C_2alkoxycarbonyl.

20. (Currently Amended) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein Ar represents benzo[1,3]dioxol-5-yl, 2,3-dihydro-1-benzofuran-6-yl, 2,3-dihydro-1-benzofuran-5-yl, chroman-6-yl, chroman-7-yl, ~~1H-indol-5-yl, 1H-indazol-5-yl,~~ 1,2,3,4-tetrahydro-quinolin-6-yl or 2,3-dihydro-benzo[1,4]dioxin-6-yl, each of which is substituted with from 0 to 2 substituents independently chosen from hydroxy, halogen, C_1-C_2 alkyl and C_1-C_2alkoxy.

21. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein Ar represents benzo[1,3]dioxol-5-yl or 2,3-dihydro-benzo[1,4]dioxin-6-yl.

22-23. (Cancelled).

24. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein R is morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, azetidinyl, homopiperidinyl, homomorpholinyl, homopiperazinyl or thiomorpholinyl, each of which substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, COOH, C_1-C_3alkyl and C_1-C_3alkoxy.

25. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein:

R_2 is propyl, butyl, pentyl or 3-methylbutyl;

R_3 is hydrogen;

R_5 is hydrogen;

R_6 is hydrogen, methyl or ethyl; and

Ar represents phenyl fused to a 5- to 7-membered saturated or partially unsaturated ring having 0, 1 or 2 ring atoms independently chosen from N, O and S with remaining ring atoms being carbon, and wherein the phenyl fused to a 5- to 7-membered ring is substituted with substituted with from 0 to 2 substituents independently chosen from hydroxy, halogen, C_1-C_2 alkyl and C_1-C_2alkoxy.

26-27. (Cancelled).

28. (Currently Amended) A compound or pharmaceutically acceptable form thereof according to ~~claim 26~~claim 25, wherein R_4 is:

(i) benzyl substituted with from 0 to 2 substituents independently chosen from hydroxy, halogen, amino, cyano, -COOH, -$CONH_2$, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, C_1-C_2alkyl, mono- and di-(C_1-C_2)alkylamino, C_1-C_2alkoxy, C_1-C_2alkanoyl, and C_1-C_2alkoxycarbonyl; or

(ii) benzyl fused to a 5- to 7-membered saturated or partially unsaturated ring having 0, 1 or 2 ring atoms chosen from N, O, and S with remaining ring atoms being carbon, wherein the benzyl fused to a 5- to 7-membered ring is substituted with from 0 to 2 substituents independently chosen from hydroxy, halogen, C_1-C_2alkyl and C_1-C_2alkoxy.

29. (Original) A compound or pharmaceutically acceptable form thereof according to claim 25, wherein:

R_1 is hydrogen, hydroxy, halogen, amino, cyano, trifluoromethyl, pentafluoroethyl, difluoromethyl, trifluoromethoxy or difluoromethoxy; and

R is morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, azetidinyl, homopiperidinyl, homomorpholinyl, homopiperazinyl or thiomorpholinyl, each of which substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, COOH, C_1-C_3alkyl and C_1-C_3alkoxy.

30. (Cancelled).

31. (Original) A compound or pharmaceutically acceptable form thereof according to claim 29, wherein R_4 is

(i) benzyl substituted with from 0 to 2 substituents independently chosen from hydroxy, halogen, amino, cyano, -COOH, -$CONH_2$, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, C_1-C_2alkyl, mono- and di-(C_1-C_2)alkylamino, C_1-C_2alkoxy, C_1-C_2alkanoyl and C_1-C_2alkoxycarbonyl; or

(ii) benzyl fused to a 5- to 7-membered saturated or partially unsaturated ring having 0, 1 or 2 ring atoms chosen from N, O, and S with remaining ring atoms being carbon, wherein the benzyl fused to a 5- to 7-membered ring is substituted with from 0 to 2 substituents independently chosen from hydroxy, halogen, C_1-C_2alkyl and C_1-C_2alkoxy.

32. (Original) A compound or pharmaceutically acceptable form thereof according to claim 1, wherein the compound exhibits an IC_{50} of 500 nM or less in a standard *in vitro* C5a receptor-mediated chemotaxis or calcium mobilization assay.

33. (Original) A compound or pharmaceutically acceptable form thereof according to claim 1, wherein the compound exhibits an IC_{50} of 25 nM or less in a standard *in vitro* C5a receptor-mediated chemotaxis or calcium mobilization assay.

34. (Original) A compound or pharmaceutically acceptable form thereof according to claim 1, wherein the compound exhibits less than 5% agonist activity in a GTP binding assay.

35. (Original) A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable form thereof according to claim 1, in combination with a physiologically acceptable carrier or excipient.

36. (Original) A method for inhibiting signal-transducing activity of a cellular C5a receptor, comprising contacting a cell expressing C5a receptor with at least one

compound or pharmaceutically acceptable form thereof according to claim 1, and thereby reducing signal transduction by the C5a receptor.

37. (Original) A method according to claim 36, wherein the cell is contacted *in vivo* in an animal.

38. (Original) A method according to Claim 37, wherein the animal is a human.

39. (Original) A method of inhibiting binding of C5a to C5a receptor *in vitro*, the method comprising contacting C5a receptor with at least one compound or pharmaceutically acceptable form thereof according to claim 1, under conditions and in an amount sufficient to detectably inhibit C5a binding to C5a receptor.

40. (Original) A method of inhibiting binding of C5a to C5a receptor in a human patient, comprising contacting cells expressing C5a receptor with at least one compound or pharmaceutically acceptable form thereof according to claim 1, in an amount sufficient to detectably inhibit C5a binding to cells expressing a cloned C5a receptor *in vitro*, and thereby inhibiting binding of C5a to the C5a receptor in the patient.

41. (Original) A method for treating a patient suffering from rheumatoid arthritis, psoriasis, cardiovascular disease, reperfusion injury, or bronchial asthma comprising administering to the patient a C5a receptor modulatory amount of a compound or pharmaceutically acceptable form thereof according to claim 1.

42. (Original) A method for treating a patient suffering from stroke, myocardial infarction, atherosclerosis, ischemic heart disease, or ischemia-reperfusion injury comprising administering to the patient a C5a receptor modulatory amount of a compound or pharmaceutically acceptable form thereof according to claim 1.

43. (Original) A method for inhibiting C5a receptor-mediated cellular chemotaxis, comprising contacting mammalian white blood cells with a C5a receptor

modulatory amount of a compound or pharmaceutically acceptable form thereof according to claim 1.

44. (Original) A method for localizing C5a receptor in a tissue sample, comprising:

(a) contacting the tissue sample containing C5a receptor with a detectably labeled compound according to claim 1 under conditions that permit binding of the compound to C5a receptors; and

(b) detecting the bound compound.

45. (Original) A packaged pharmaceutical preparation, comprising:

(a) a pharmaceutical composition according to claim 35 in a container; and

(b) instructions for using the composition to treat a patient suffering from rheumatoid arthritis, psoriasis, cardiovascular disease, reperfusion injury, or bronchial asthma.

46. (Original) A packaged pharmaceutical preparation

(a) a pharmaceutical composition according to claim 35 in a container; and

(b) instructions for using the composition to treat stroke, myocardial infarction, atherosclerosis, ischemic heart disease, or ischemia-reperfusion injury.

47. (Original) A pharmaceutical composition according to claim 35, wherein the pharmaceutical composition is formulated as an injectible fluid, an aerosol, a cream, a gel, a pill, a capsule, a syrup, or a transdermal patch.